share_log
Reuters ·  Apr 1 11:00
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for Empaveli® (Pegcetacoplan) for C3G and Primary Ic-Mpgn
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 280

Recommended

Write a comment